Sign Out
Known hypersensitivity to felodipine or any other component of the product.
Unstable angina pectoris.
Pregnancy.
Other dihydropyridines because of the theoretical risk of cross-reactivity.
Patients with clinically significant aortic stenosis, haemodynamically significant cardiac valvular obstruction, dynamic cardiac outflow obstruction, uncompensated heart failure and during or within one month of an acute myocardial infarction.
As with other calcium channel blockers, felodipine should be discontinued in patients who develop cardiogenic shock.
